Trinity Biotech (NASDAQ:TRIB) Shares Up 0.7% – Here’s What Happened

Shares of Trinity Biotech plc (NASDAQ:TRIB) traded up 0.7% during mid-day trading on Friday . The stock traded as high as $0.93 and last traded at $0.91. 34,204 shares were traded during mid-day trading, a decline of 92% from the average session volume of 417,740 shares. The stock had previously closed at $0.90.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Trinity Biotech in a research report on Friday, August 30th. They set a “buy” rating on the stock.

Trinity Biotech Stock Up 0.7 %

The firm has a market cap of $6.90 million, a price-to-earnings ratio of -0.40 and a beta of 0.97. The firm has a 50 day moving average of $1.46 and a 200 day moving average of $1.95.

Institutional Trading of Trinity Biotech

A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC lifted its stake in shares of Trinity Biotech plc (NASDAQ:TRIB) by 7.8% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 359,810 shares of the company’s stock after acquiring an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned 4.72% of Trinity Biotech worth $390,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 78.97% of the company’s stock.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.